There is a ton of bearish perspective over there. Lemmy, frustrated, patientsdeservebest, carboat, etc etc... Anybody who wants to decide for themselves can check it out. it does have its disadvantages but for content, scientific and technical due diligence, it crushes this clown show. Any adult can decide for themselves. Bashers hate it.
sauve9, thank you again for bringing ACAD to the attention of this board when ACAD was trading in the 2s. I followed you into that trade and sold out for a big 250% gain. I of course wish I had bought more and held much longer, but that is on me. YTB!
Long answer to that question. I'be got to make it brief: it's been exactly one year since a big two day spike on 36 million shares which happened on very little news, so any shares aquire then hedged by the big short that dropped the price again are now capital gains. First look in to trial could happen any day. CEO at Roth on Monday. ER on the 12th and it's been 1 year since CEO said "I look forward to partnerships coming to fruition over the upcoming year(forward looking statement but still). March 28th HCC IST final round of data to be presented at the podium (rather than just a poster). Breast IST data is overdue (both breast and HCC have been forwarded with confident language by management). Then big conferences April 18-20.
Lots of potential. it all comes down to Bavituximab, it's efficatiousness and MOA.
Apple, which is known for vertically integrating their supply chain, could buy the mine on the other side of the California border and mine gold at cost for all those gold watches they just announced they plan to sell (1 million a month).